Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q3 2021 · 10-Q
Revenue$121.34M$121.34M−3.3% vs Q3 2020 Net Income-$20.35M-$20.35MN/M vs Q3 2020 EPS Diluted-$0.17-$0.17N/M vs Q3 2020 Gross Profit$47,239,000−12.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,767,000N/M Free Cash Flowderived-$22,744,000N/M Margins · derivedGross margin38.9%−4.2 pt vs Q3 2020
Operating margin-32.7%−36.5 pt vs Q3 2020
Net margin-16.8%−18.8 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 4, 2021 · 35 d after period end